Sökning: id:"swepub:oai:DiVA.org:umu-177187" >
Selenium supplement...
Selenium supplementation in patients with peripartum cardiomyopathy : a proof-of-concept trial
-
- Karaye, Kamilu M. (författare)
- Umeå universitet,Kardiologi,Department of Medicine, Bayero University, Kano, Nigeria; Department of Medicine, Aminu Kano Teaching Hospital, Kano, Nigeria
-
Sa'idu, Hadiza (författare)
-
Balarabe, Suleiman A. (författare)
-
visa fler...
-
Ishaq, Naser A. (författare)
-
Sanni, Bushra (författare)
-
Abubakar, Haruna (författare)
-
Mohammed, Baba Lawan (författare)
-
Abdulsalam, Tijjani (författare)
-
Tukur, Jamilu (författare)
-
Mohammed, Idris Y. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2020-10-21
- 2020
- Engelska.
-
Ingår i: BMC Cardiovascular Disorders. - : BioMed Central. - 1471-2261 .- 1471-2261. ; 20:1
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://umu.diva-por... (primary) (Raw object)
-
https://bmccardiovas...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: We studied the efficacy and safety of selenium supplementation in patients who had peripartum cardiomyopathy (PPCM) and selenium deficiency.Methods: We randomly assigned 100 PPCM patients with left ventricular ejection fraction (LVEF) < 45% and selenium deficiency (< 70 mu g/L) to receive either oral Selenium (L-selenomethionine) 200 mu g/day for 3 months or nothing, in addition to recommended therapy, in an open-label randomised trial. The primary outcome was a composite of persistence of heart failure (HF) symptoms, unrecovered LV systolic function (LVEF < 55%) or death from any cause.Results: Over a median of 19 months, the primary outcome occurred in 36 of 46 patients (78.3%) in the selenium group and in 43 of 54 patients (79.6%) in the control group (hazard ratio [HR] 0.69; 95% confidence interval [CI] 0.43-1.09; p = 0.113). Persistence of HF symptoms occurred in 18 patients (39.1%) in the selenium group and in 37 patients (68.5%) in the control group (HR 0.53; 95% CI 0.30-0.93; p = 0.006). LVEF < 55% occurred in 33 patients (71.7%) in the selenium group and in 38 patients (70.4%) in the control group (HR 0.91; 95% CI 0.57-1.45; p = 0.944). Death from any cause occurred in 3 patients (6.5%) in the selenium group and in 9 patients (16.7%) in the control group (HR 0.37; 95% CI 0.10-1.37; p = 0.137).Conclusions: In this study, selenium supplementation did not reduce the risk of the primary outcome, but it significantly reduced HF symptoms, and there was a trend towards a reduction of all-cause mortality.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- Peripartum cardiomyopathy
- Selenium supplementation
- Outcomes
- Mortality
- PEACE registry
- Nigeria
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Karaye, Kamilu M ...
-
Sa'idu, Hadiza
-
Balarabe, Suleim ...
-
Ishaq, Naser A.
-
Sanni, Bushra
-
Abubakar, Haruna
-
visa fler...
-
Mohammed, Baba L ...
-
Abdulsalam, Tijj ...
-
Tukur, Jamilu
-
Mohammed, Idris ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
BMC Cardiovascul ...
- Av lärosätet
-
Umeå universitet